China Journal of Leprosy and Skin Diseases ›› 2024, Vol. 40 ›› Issue (8): 533-537.doi: 10.12144/zgmfskin202408533

• Original Articles • Previous Articles     Next Articles

Efficacy and safety of abrocitinib and dupilumab in the treatment of moderate to severe atopic dermatitis

Dilinuer TAXIMAIMAITI, Palida ABULIZI   

  1. The First Affiliated Hospital of Xinjiang Medical University, Urumchi 830000, China
  • Online:2024-08-15 Published:2024-07-29

PDF (PC)

120

Like

Abstract: Objective: To evaluate efficacy and safety of abrocitinib and dupilumab in the treatment of moderate to severe atopic dermatitis (AD). Methods: The clinical data of 104 patients with moderate and severe AD who were admitted to dermatology department of our hospital from January to June 2023 were retrospectively analyzed. Fifty-one patients (group A) received abrocitinib 200 mg/day orally, and 53 patients (group D) received subcutaneous dupilumab 300 mg every two weeks (baseline load dose 600 mg). The treatment period was 24 weeks. EASI scores, dermatological life quality index (DLQI) and numeric rating scale for pruritus (P-NRS) were analyzed at 0, 4, 8, 12, 16 and 24 weeks after treatment. Serum total IgE levels and eosinophilic counts were analyzed at week 0, week 8, week 16 and week 24 after treatment. Treatment-emergent adverse events were analyzed. Results: After treatment, EASI, P-NRS and DLQI levels in group A and Group D were significantly decreased compared with those before treatment, with significant differences (Ps<0.05). Compared with group D, EASI, P-NRS and DLQI levels in group A were more significantly decreased. With the extension of treatment course, the serum total IgE level and eosinophils count showed a gradually decreasing trend between the two groups, with no significant difference (Ps>0.05). The incidence of conjunctivitis in group D was significantly higher than that in group A, with a significant difference (P<0.05). The incidence of nausea in group A was significantly higher than that in group D, with a significant difference (P<0.05). Conclusion: Both abrocitinib and dupilumab can significantly relieve pruritis and improve quality of life in patients with moderate to severe atopic dermatitis at 24 weeks after treatment, but abrocitinib is more effective in relieving pruritis. Both abrocitinib and dupilumab have high safety, but require attention for gastrointestinal symptoms and conjunctivitis, respectively.

Key words: abrocitinib, dupilumab, atopic dermatitis, adults, retrospective study